Screen-Detected Breast Cancer Tied to Favorable Tumor Profile and 43% Lower Mortality

Screen-detected breast cancers (vs non-screen-detected) were earlier stage, lower grade, and had 43% lower all-cause mortality (5-year survival 92.9% vs 73.6%) in a cohort of 1,023 women. Benefit persisted in those ≥75 years.

• Screen-detected cancers were more often node-negative (85.5% vs 59.1%), non-metastatic (98.6% vs 82.4%), and treated with lumpectomy (72.1% vs 50.2%), p<0.001 for all.
• In non-screen-detected group, tumor stage worsened with increasing time since last negative screen (p<0.001).
• After adjustment, screen-detection was associated with a 43% lower risk of all-cause death (HR 0.57, p=0.003) and benefit persisted in women ≥75 years (HR 0.44, p=0.014).

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.